Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001674324-25-000005
Filing Date
2025-11-18
Accepted
2025-11-18 16:38:22
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 14142
  Complete submission text file 0001674324-25-000005.txt   15954
Mailing Address 4 EMBARCADERO CENTER, SUITE 3110 SAN FRANCISCO CA 94111
Business Address 4 EMBARCADERO CENTER, SUITE 3110 SAN FRANCISCO CA 94111 (415) 993-8565
5AM Ventures V, L.P. (Filed by) CIK: 0001674324 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MA 02210
Business Address ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MA 02210 857-305-1825
Entrada Therapeutics, Inc. (Subject) CIK: 0001689375 (see all company filings)

EIN.: 813983399 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-93025 | Film No.: 251495324
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)